Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 137

Sort by

Sort Order Select

Journal Articles

Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

Blood (2024) 144 (Supplement 1): 384.

https://doi.org/10.1182/blood-2024-203344

Published: 2024

Journal Articles

Evaluation of Venetoclax Duration in Venetoclax-Azacitidine Regimen for Untreated Acute Myeloid Leukemia: Real World Experience from Hokkaido Leukemia Net

Blood (2024) 144 (Supplement 1): 6063.

https://doi.org/10.1182/blood-2024-200013

Published: 2024

Journal Articles

Evaluation of Lymphocyte Immunity in Patients Treated with Venetoclax-Azacitidine for Acute Myeloid Leukemia

Minoru Kanaya, Toma Suzuki, Sayaka Kajikawa, Emi Yokoyama, Koh Izumiyama, Makoto Saito, Masanobu Morioka, Akio Mori, Toshihiro Matsukawa, Masahiro Onozawa, Takanori Teshima, Takeshi Kondo

Blood (2024) 144 (Supplement 1): 6061.

https://doi.org/10.1182/blood-2024-198084

Published: 2024

Journal Articles

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Blood (2024) 144 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2024-201730

Published: 2024

Journal Articles

Combination of Low White Blood Cell Count and Impaired Renal Function Is a Risk Factor for Higher Concentrations of Venetoclax and Prolonged Neutropenia in AML Patients with Venetoclax Combined Regimen: Real World Experience in the Japanese Cohort

Minoru Kanaya, Yuji Mukai, Mirei Kobayashi, Sayaka Kajikawa, Toma Suzuki, Emi Yokoyama, Koh Izumiyama, Makoto Saito, Masanobu Morioka, Akio Mori, Toshihiro Matsukawa, Masahiro Onozawa, Goichi Yoshimoto, Mitsuru Moriyama, Sunggi Chi, Takanori Teshima, Yosuke Minami, Masato Honmma, Takeshi Kondo

Blood (2024) 144 (Supplement 1): 2930.

https://doi.org/10.1182/blood-2024-198943

Published: 2024

Journal Articles

Early Initiation of Calcineurin Inhibitor Induces CD8 + Transitory Exhausted-like and CD4 + Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide

Blood (2024) 144 (Supplement 1): 903.

https://doi.org/10.1182/blood-2024-197873

Published: 2024

Journal Articles

Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation

Yumika Saito, Daigo Hashimoto, Keisuke Kojima, Shihori Tsukamoto, Tomoe Ichiki, Toru Miyajima, Wenyu Li, Shinpei Harada, Zixuan Zhang, Hajime Senjo, Yuta Hasegawa, Takahide Ara, Takanori Teshima

Blood (2024) 144 (Supplement 1): 902.

https://doi.org/10.1182/blood-2024-201237

Published: 2024

Journal Articles

Gvhd-Induced Inflammatory Memory in Intestinal Stem Cells Enhances IFN-γ-Induced Antigen Presentation and Apoptosis of Intestinal Epithelial Cells

Toru Miyajima, Daigo Hashimoto, Keisuke Kojima, Shihori Tsukamoto, Tomoe Ichiki, Yumika Saito, Wenyu Li, Zixuan Zhang, Shinpei Harada, Hajime Senjo, Yuki Yokoi, Yuta Hasegawa, Hiroyuki Ohigashi, Takahide Ara, Kiminori Nakamura, Koji Taniguchi, Takanori Teshima

Blood (2024) 144 (Supplement 1): 260.

https://doi.org/10.1182/blood-2024-202926

Published: 2024

Journal Articles

Reduced FDG Uptake in the Brain on Baseline 18FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Intravascular Large B-Cell Lymphoma and Advanced-Stage Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3096.

https://doi.org/10.1182/blood-2024-204976

Published: 2024

Journal Articles

GVHD targets organoid-forming bile duct stem cells in a TGF-β–dependent manner

Yuta Hasegawa, Daigo Hashimoto, Zixuan Zhang, Toru Miyajima, Yumika Saito, Wenyu Li, Ryo Kikuchi, Hajime Senjo, Tomoko Sekiguchi, Takahiro Tateno, Xuanzhong Chen, Emi Yokoyama, Shuichiro Takahashi, Hiroyuki Ohigashi, Takahide Ara, Eiko Hayase, Isao Yokota, Takanori Teshima

Blood (2024) 144 (8): 904–913.

https://doi.org/10.1182/blood.2023023060

Published: 2024

Includes: Supplemental data

Journal Articles

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Blood (2024) 143 (17): 1713–1725.

https://doi.org/10.1182/blood.2023021567

Published: 2024

Includes: Supplemental data

Journal Articles

Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma

Masahiro Chiba, Joji Shimono, Keito Suto, Takashi Ishio, Tomoyuki Endo, Hideki Goto, Hiroo Hasegawa, Michiyuki Maeda, Takanori Teshima, Yibin Yang, Masao Nakagawa

Blood (2024) 143 (14): 1379–1390.

https://doi.org/10.1182/blood.2023021423

Published: 2024

Includes: Supplemental data

Journal Articles

Low-Dose ATG Has the Same Risk of CMV Reactivation after Allogeneic PBSCT As Ptcy, but Letemovir Is Effective in Preventing CMV Reactivation

Takahide Ara, Yuta Hasegawa, Hiroyuki Ohigashi, Toshihiro Matsukawa, Souichi Shiratori, Atsushi Yasumoto, Hideki Goto, Masahiro Onozawa, Masao Nakagawa, Kaoru Kahata, Tomoyuki Endo, Daigo Hashimoto, Takanori Teshima

Blood (2023) 142 (Supplement 1): 3546.

https://doi.org/10.1182/blood-2023-191306

Published: 2023

Journal Articles

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Blood (2023) 142 (Supplement 1): 601.

https://doi.org/10.1182/blood-2023-180936

Published: 2023

Journal Articles

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Robert Zeiser, Domenico Russo, Ron Ram, Shahrukh K Hashmi, Ronjon Chakraverty, Jan Moritz Middeke, Maurizio Musso, Sebastian Giebel, Ant Uzay, Peter Langmuir, Nada Hamad, Xuechan Li, Maanasa Gowda, Tommaso Stefanelli, Stephanie J. Lee, Takanori Teshima, Franco Locatelli

Blood (2023) 142 (Supplement 1): 654.

https://doi.org/10.1182/blood-2023-172590

Published: 2023

Journal Articles

Delayed Initiation of Calcineurin Inhibitor Is Critical for Tolerance Induction By Posttransplant Cyclophosphamide

Hajime Senjo, Daigo Hashimoto, Satomi Okada, Shimpei I Kubota, Ayumu Ito, Takashi Tanaka, Yumika Saito, Toru Miyajima, Wenyu Li, Zixuan Zhang, Shinpei Harada, Yuta Hasegawa, Hiroyuki Ohigashi, Takahide Ara, Yoshinori Hasegawa, Yoshihiro Inamoto, Masaaki Murakami, Takahiro Fukuda, Takanori Teshima

Blood (2023) 142 (Supplement 1): 2041.

https://doi.org/10.1182/blood-2023-181560

Published: 2023

Journal Articles

Genetic Mutation and Outcome of Venetoclax-Based Therapy in Newly Diagnosed AML in the Real World: Hokkaido Leukemia Net Study

Blood (2023) 142 (Supplement 1): 1470.

https://doi.org/10.1182/blood-2023-173909

Published: 2023

Journal Articles

Baseline 18 f-Fluorodeoxyglucose PET/CT Radiomics Predicts Outcome in Newly Diagnosed Intravascular Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 6321.

https://doi.org/10.1182/blood-2023-188507

Published: 2023

Journal Articles

Genome-Wide CRISPR Screen Identifies MAD2L1BP, ANAPC15 and SLC39A7 As Intrinsic Regulators for Brentuximab Vedotin Sensitivity in Peripheral T-Cell Lymphoma Cells

Keito Suto, Masahiro Chiba, Takashi Ishio, Hideki Goto, Tomoyuki Endo, Michiyuki Maeda, Takanori Teshima, Masao Nakagawa

Blood (2023) 142 (Supplement 1): 51.

https://doi.org/10.1182/blood-2023-180348

Published: 2023

Journal Articles

TP53 and CDKN2A alterations Define a Poor Prognostic Subgroup in Patients with Nodal T-Follicular Helper Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1630.

https://doi.org/10.1182/blood-2023-173638

Published: 2023

NARROW

Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

Evaluation of Venetoclax Duration in Venetoclax-Azacitidine Regimen for Untreated Acute Myeloid Leukemia: Real World Experience from Hokkaido Leukemia Net

Evaluation of Lymphocyte Immunity in Patients Treated with Venetoclax-Azacitidine for Acute Myeloid Leukemia

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Combination of Low White Blood Cell Count and Impaired Renal Function Is a Risk Factor for Higher Concentrations of Venetoclax and Prolonged Neutropenia in AML Patients with Venetoclax Combined Regimen: Real World Experience in the Japanese Cohort

Early Initiation of Calcineurin Inhibitor Induces CD8 + Transitory Exhausted-like and CD4 + Cytotoxic T Cells, Maintaining Responsiveness to PD-1 Blockade and Contributing to the Development of Chronic Gvhd after Post-Transplant Cyclophosphamide

Ropeginterferon Alfa-2b Induces Apoptosis and Differentiation of Leukemia Stem Cells and Separates GVL Effects from Gvhd after Allogeneic Hematopoietic Cell Transplantation

Gvhd-Induced Inflammatory Memory in Intestinal Stem Cells Enhances IFN-γ-Induced Antigen Presentation and Apoptosis of Intestinal Epithelial Cells

Reduced FDG Uptake in the Brain on Baseline 18FDG PET/CT Predicts Worse Prognosis of Newly Diagnosed Intravascular Large B-Cell Lymphoma and Advanced-Stage Diffuse Large B-Cell Lymphoma

GVHD targets organoid-forming bile duct stem cells in a TGF-β–dependent manner

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma

Low-Dose ATG Has the Same Risk of CMV Reactivation after Allogeneic PBSCT As Ptcy, but Letemovir Is Effective in Preventing CMV Reactivation

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Delayed Initiation of Calcineurin Inhibitor Is Critical for Tolerance Induction By Posttransplant Cyclophosphamide

Genetic Mutation and Outcome of Venetoclax-Based Therapy in Newly Diagnosed AML in the Real World: Hokkaido Leukemia Net Study

Baseline 18 f-Fluorodeoxyglucose PET/CT Radiomics Predicts Outcome in Newly Diagnosed Intravascular Large B-Cell Lymphoma

Genome-Wide CRISPR Screen Identifies MAD2L1BP, ANAPC15 and SLC39A7 As Intrinsic Regulators for Brentuximab Vedotin Sensitivity in Peripheral T-Cell Lymphoma Cells

TP53 and CDKN2A alterations Define a Poor Prognostic Subgroup in Patients with Nodal T-Follicular Helper Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only